Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $471 | $491 | $406 | $416 |
| % Growth | -4.2% | 20.9% | -2.3% | – |
| Cost of Goods Sold | $103 | $102 | $92 | $92 |
| Gross Profit | $368 | $389 | $314 | $324 |
| % Margin | 78.1% | 79.2% | 77.3% | 78% |
| R&D Expenses | $341 | $525 | $527 | $258 |
| G&A Expenses | $146 | $154 | $192 | $129 |
| SG&A Expenses | $391 | $454 | $453 | $345 |
| Sales & Mktg Exp. | $245 | $300 | $260 | $216 |
| Other Operating Expenses | -$18 | -$1 | -$31 | -$7 |
| Operating Expenses | $714 | $978 | $949 | $596 |
| Operating Income | -$347 | -$590 | -$650 | -$279 |
| % Margin | -73.6% | -120.1% | -160% | -67% |
| Other Income/Exp. Net | -$394 | -$147 | -$506 | -$99 |
| Pre-Tax Income | -$741 | -$735 | -$1,156 | -$378 |
| Tax Expense | -$23 | -$6 | -$34 | -$6 |
| Net Income | -$714 | -$704 | -$1,058 | -$374 |
| % Margin | -151.7% | -143.2% | -260.2% | -89.8% |
| EPS | -1.63 | -1.61 | -2.42 | -0.85 |
| % Growth | -1.2% | 33.5% | -184.7% | – |
| EPS Diluted | -1.63 | -1.61 | -2.42 | -0.85 |
| Weighted Avg Shares Out | 438 | 438 | 438 | 439 |
| Weighted Avg Shares Out Dil | 438 | 438 | 438 | 439 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $34 | $35 | $49 |
| Interest Expense | $17 | $63 | $45 | $2 |
| Depreciation & Amortization | $111 | $125 | $112 | $52 |
| EBITDA | -$613 | -$548 | -$999 | -$324 |
| % Margin | -130.2% | -111.5% | -245.9% | -77.9% |